FIBRICOR (fenofibric acid) tablets
Go to Patient Site

Patient Savings

Savings for Your Patients

Fibricor Copay Card
 

YOUR PATIENTS CAN SAVE WITH THE
FIBRICOR® PATIENT SAVINGS CARD

They pay as little as $15 for 30 days*

*Limitations apply. Reimbursement limited to $200 per month

 

 

PATIENT INSTRUCTIONS:

  1. Get a valid prescription for FIBRICOR or Fenofibric Acid Tablets. Ask your doctor if FIBRICOR is right for you.
  2. Fill your prescription by taking your prescription and the Card to your pharmacy.
  3. Many eligible commercially insured patients may receive their prescription for as little as $15.*

 

*Program eligibility and restrictions apply. This offer is only valid for FIBRICOR, manufactured for Athena Bioscience LLC, or Fenofibric Acid, manufactured for Palmetto Pharmaceuticals, Inc. No substitutions permitted.

 

If you need a FIBRICOR Patient Savings Card for your patient, please visit the Patient Savings Card page.

FIBRICOR® (fenofibric acid) Important Safety Information

FIBRICOR® is contraindicated in patients with severe renal impairment including those on dialysis, with active liver disease including primary biliary cirrhosis and unexplained persistent liver function abnormalities and with gallbladder disease. FIBRICOR is also contraindicated in nursing mothers and patients with hypersensitivity to fenofibric acid or fenofibrate.

The most commonly reported adverse reactions (>2% and at least 1% greater than placebo) are abnormal liver tests, increased AST, increased ALT, increased CPK, and rhinitis.

Fenofibrate can increase serum transaminases. Monitor liver tests, including ALT, periodically during therapy. In addition, myopathy and rhabdomyolysis have been reported in patients taking fenofibrate. Fibrates increase the risk for myopathy and have been associated with rhabdomyolysis. The risk for serious muscle toxicity appears to be increased in elderly patients and in patients with diabetes, renal failure, or hypothyroidism. Patients should be advised to report promptly unexplained muscle pain, tenderness or weakness particularly if accompanied by malaise or fever. Creatine phosphokinase (CPK) levels should be assessed in these patients. Treatment should be discontinued if markedly elevated CPK levels occur or myopathy/myositis is suspected or diagnosed. Fenofibrate can reversibly increase serum creatinine levels. The clinical relevance of these findings is unknown. Patients with renal impairment and those at risk for renal insufficiency should be periodically monitored. Fenofibrates may increase cholesterol excretion into the bile, leading to risk of cholelithiasis. If cholelithiasis is suspected, gallbladder studies are indicated. Discontinue treatment if gallstones are found.

You are encouraged to report adverse reactions to Athena Bioscience, LLC at 1-833-874-2664 or to the FDA: 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see the accompanying Full Prescribing Information.